Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02911142
Title Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Etoposide + Lenalidomide + Prednisone + Rituximab + Vincristine Sulfate

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.